- Based on discussions with the FDA, Inhibrx Inc INBX has the potential to pursue accelerated approval for INBRX-101 for emphysema due to alpha-1 antitrypsin deficiency (AATD) using functional alpha-1 antitrypsin (AAT) serum levels as the surrogate endpoint.
- Inhibrx also detected INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients tested in the Phase 1 study.
- Related: Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder.
- Inhibrx plans to initiate in Q1 of 2023 a potential registration-enabling trial using functional AAT as a surrogate endpoint.
- Based on data from the completed Phase 1 study, INBRX-101 is predicted to maintain patients above the lower threshold of the normal range and achieve an average level of functional AAT.
- The FDA also requested additional data on the correlation between functional AAT levels and the clinical benefit of AATD to further support serum AAT levels as a surrogate endpoint that is reasonably likely to predict clinical benefit.
- Price Action: INBX shares are up 30.9% at $26.41 during the premarket session on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.